Search

News Current Recommendations of the Expert Panel on the Management of von Willebrand Disease

Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new recommendations from 2021 regarding the care of people with vWD are evidence-based and supported by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation USA (NHF), and the World Federation of Hemophilia (WFH). We bring you a concise summary of the key points.

Source: Von Willebrand Disease 4. 1. 2022

News Summary of Guidelines for the Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Pediatric Patients with Leukemia and Post Hematopoietic Stem Cell Transplantation

Invasive fungal diseases are a significant cause of morbidity and mortality among immunocompromised pediatric patients with leukemia and post-hematopoietic stem cell transplantation. During the 8th European Conference on Infections in Leukemia (ECIL-8) in 2020, the pediatric group reviewed and updated recommendations for the diagnosis, prevention, and treatment of invasive fungal infections in pediatric patients.

Source: Anti-Infectives 18. 11. 2021

News Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin

Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases. Empagliflozin is among the modern oral antidiabetic medications, and in 2015 it became a pioneer among diabetes treatments shown to reduce the incidence of major CV events. It has also been proven to reduce the risk of hospitalization for heart failure.

Source: Heart Failure 18. 11. 2021

News Reversal of Dabigatran Effects with Idarucizumab in Patients Requiring Urgent Procedures: Subanalysis of the RE-VERSE AD Study

The effect of idarucizumab as a reversal agent in patients treated with dabigatran in situations requiring urgent surgery or other invasive procedures was evaluated in a subanalysis from the RE-VERSE AD study published in 2021.

Source: Anticoagulant Treatment 18. 11. 2021

News Safety of Dabigatran According to a Meta-Analysis of 7 Randomized Controlled Trials

Dabigatran is a direct thrombin inhibitor from the group of direct oral anticoagulants (DOACs), developed as an alternative to vitamin K antagonists. The aim of the recently published meta-analysis was to compare the risk of bleeding, fatal adverse events, and mortality in patients treated with dabigatran and conventional therapy.

Source: Anticoagulant Treatment 18. 11. 2021

News Efficacy and Safety of Dual Bronchodilator Therapy for COPD –⁠ From Randomized Clinical Trials to Real-World Clinical Practice

Dual bronchodilator therapy (LAMA + LABA) represents one of the mainstays of treating chronic obstructive pulmonary disease (COPD). The aim of the recent systematic review presented below was to assess the efficacy and safety of this dual therapy compared to monotherapy or other combinations in the context of clinical trials and real-world clinical practice.

Source: Treatment of Asthma and COPD 18. 11. 2021

News Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?

It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) have a higher risk of severe course of common viral respiratory diseases. A study by Belgian authors involving several hundred individuals evaluated the risk of ICU admission and death due to COVID-19 in patients with asthma and COPD compared to patients without these conditions. The other goal was to determine whether these risks are influenced by inhalation corticosteroid therapy or not.

Source: Treatment of Asthma and COPD 8. 11. 2021

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs –⁠ sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) –⁠ in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.

Source: Cardiovascular Continuum 18. 11. 2021

News Subclinical Hypothyroidism Associated with the Use of Allopurinol? What the Results of a Large Multicenter Study Suggested

Allopurinol is a widely used drug for the treatment of hyperuricemia and gout. The retrospective study presented below investigated whether its long-term use is associated with an increased risk of developing subclinical hypothyroidism.

Source: Thyroid Disorders 18. 11. 2021

News Cell-Based Implant as a Stable System for Biological Therapy Delivery

A team of scientists from Washington University in St. Louis focused on the possibility of delivering biological inhibitors for the treatment of rheumatoid arthritis using modified induced pluripotent stem cells. To verify the effectiveness of the therapy, they used a mouse model of rheumatoid arthritis, and their results represent progress in the development of rheumatoid arthritis treatment.

Source: Arthritis 19. 11. 2021

News Comparable Long-term Safety of Tofacitinib and Biologics in RA Treatment –⁠ Data from a US Registry

An analysis of the long-term safety profile of tofacitinib in real clinical practice was published in the journal of the American College of Rheumatology (ACR). Patients with rheumatoid arthritis (RA) who started treatment with tofacitinib showed a similar frequency of predefined adverse events of special interest compared to a cohort treated with biological disease-modifying antirheumatic drugs (bDMARDs).

Source: Arthritis 18. 11. 2021

News HAE in the Otolaryngologist's Office: How to Handle a Laryngeal Attack?

Hereditary angioedema (HAE) can be encountered in emergency rooms and specialist offices. Patients with this rare disorder are often misdiagnosed with a more common condition, and they may learn their correct diagnosis only after many years. This is because HAE manifests with a combination of symptoms that are typical of various other diseases. What should pediatricians, otorhinolaryngologists, and gastroenterologists be aware of? Providing better understanding of HAE symptoms from different specializations' perspectives and emphasizing the importance of interdisciplinary collaboration for accurate diagnosis and patient care was the focus of a professional webinar we have summarized for you.

Source: Hereditary Angioedema 19. 11. 2021

News HAE and its Management in Pediatric Patients

Hereditary angioedema (HAE) can be encountered in the emergency room as well as in specialist practices. Patients with this rare disease are often incorrectly diagnosed with other, more common conditions, and it can take many years before they receive the correct diagnosis. This is because the symptoms of HAE overlap with those of other illnesses. What should pediatricians, otolaryngologists, and gastroenterologists be aware of? To provide a better understanding of HAE symptoms from the perspective of various specialties and emphasize the importance of interdisciplinary collaboration for the correct diagnosis and care of patients with HAE, a professional webinar was held. We have prepared a summary of the most important points for you.

Source: Hereditary Angioedema 19. 11. 2021

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.

Source: Oncological Treatment 22. 11. 2021

News Pharmacotherapy of Chronic Heart Failure with Reduced EF LV -⁠ Latest ESC Recommendations

The European Society of Cardiology (ESC) issued an update in 2021 for the diagnosis and treatment of heart failure. We summarize the essential points regarding the pharmacotherapy of chronic heart failure with reduced ejection fraction.

Source: Chronic Heart Failure and Lipidology 22. 11. 2021